Clinical trials: Disorder of Upper Respiratory System
Influenza, Human
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an…
- Trial name
- NCT03314662
- Testing
- MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
- Where
- 20 sites in United States
- Volunteers
- 1,778 people, healthy volunteers welcome
- Sponsor
- Seqirus